CSCI Research Brief

Cannabinoids as Aromatase Inhibitors for Anti-Cancer Activity

Baroi, S., Saha, A., Ritesh Bachar, R., and Bachar, S.C. Cannabinoid as Potential Aromatase Inhibitor Through Molecular Modeling and Screening for Anti-Cancer Activity. Dhaka Univ. J. Pharm. Sci. 19(1): 47-58, 2020 (June 28, 2020.) doi: 10.3329/dujps.v19i1.47818

Breast cancer is the most prevalent type of cancer, with over 234,000 cases reported in the U.S. in 2015. Estrogen dependent carcinomas are among the most common types of breast cancer.  

Aromatase is an enzyme that converts cholesterol to estradiol E2, the most biologically active form of estrogen. 

The 2020 virtual screening technique and docking study looked at cannabinoids that may serve as potential inhibitors of aromatase, thus limiting the estrogen biosynthesis pathway. The study used cannabis sativa molecules to develop aromatase inhibitors via computer-based techniques in a lab-based studies. The study examined 61 cannabinoid compounds as potential anticancer drugs after ADEMT checking. ADEMT is chemical absorption, distribution, metabolism, excretion, and toxicity; these are key factors that must be checked in drug studies. A high-quality drug candidate should show an anticancer potential and appropriate ADMET properties at a level of therapeutic dosing.

Cannabinoids as Aromatase Inhibitors for Anti-Cancer Activity: Study Findings

The study identified three molecules as the most likely candidates to be further studied for their anti-tumor effects on hormone targeted breast cancer. These candidates include cannabidiorcol (CBD-C1), and cannabiripsol (CBR). And cannabitriol (CBT). These three compounds were found to have significant cytotoxic activity with the potential to be developed as very strong aromatase inhibitors.


The study revealed preliminary findings that show that some cannabinoids and compounds should be included in future studies on aromatase inhibitors for anti-cancer activity and cancer treatment modalities. Link to article:

General Disclaimer

Center for Scientific Cannabinoid Information (CSCI) has placed information, including links to other websites or content belonging to or originating from third parties, on this website as a service to the general public and for general informational and educational purposes only.  The information on this website is not intended to substitute particularized advice of specialists or qualified professionals.  No content on this website should ever be used as a substitute for direct advice from appropriate professionals or qualified specialists.  This website could include inaccuracies or typographical errors.  The materials on this website do not constitute medical advice, do not necessarily reflect the opinions of CSCI or any of its employees, agents, affiliates, or subsidiaries, and are not guaranteed to be correct, complete, or up‐to‐date.  The publications, articles, and information on this website are provided as is without warranty of any kind, either express or implied, regarding accuracy, adequacy, validity, reliability, availability, or completeness, and CSCI does not warrant, endorse, guarantee, or assume responsibility for the accuracy or reliability of any information included on this website from third-party websites linked through this website.  UNDER NO CIRCUMSTANCE SHALL CSCI HAVE ANY LIABILITY TO YOU FOR ANY LOSS OR DAMAGE OF ANY KIND INCURRED AS A RESULT OF THE USE OF THE INFORMATION CONTAINED ON THIS WEBSITE OR RELIANCE ON ANY SUCH INFORMATION PROVIDED ON THIS WEBSITE. YOUR USE OF THIS WEBSITE AND YOUR RELIANCE ON ANY INFORMATION ON THIS WEBSITE IS SOLELY AT YOUR OWN RISK.

You cannot copy content of this page